Menu
nSTRIDE® is an Autologous (from your own body) Anti-Inflammatory treatment, which is designed to treat joint pain associated with knee osteoarthritis. In laboratory testing, nSTRIDE® has been shown to protect cartilage tissue. This protective quality may slow the progression of osteoarthritis as well.4^
nSTRIDE® will be administered directly in the knee joint. Positive outcomes are possible due to the presence of high concentrations of anti-inflammatory proteins.16
These “good” proteins may help stimulate a biologic cascade, which has been shown to block cartilage destruction in osteoarthritis.4^ The pain in the joint may be reduced, and the joint function may be improved. The treatment is designed to be a single injection therapy in the doctor’s office.
The nSTRIDE® Kit processes the patient’s own blood in the clinic to concentrate white blood cells, platelets and plasma proteins into a small volume of plasma. The output is approximately 2 to 3cc of anti-inflammatory solution.
You may experience side effects (e.g. bruising, local pain or swelling) associated with the blood draw, knee injection, MRI or X-ray procedures.
There is no cure for OA.15 But successful treatment with nSTRIDE® may reduce or relieve your pain, which may increase your mobility and comfort.3 Your osteoarthritis may not improve or may get worse.
nSTRIDE® may significantly decrease or eliminate pain, reduce stiffness and help restore mobility and flexibility.1,3,14*
Pain relief may be expected after one to two weeks.3,14*
Yes. Studies have demonstrated the safety of nSTRIDE®.3
It is recommended that you minimise your activity level for 14 days and not exceed pre-injection activity levels.
Based on preclinical and early clinical results, patients may expect to see benefits for up to 24-36 months.1,2,3,14*
Patients with mild to moderate knee osteoarthritis can receive the nSTRIDE® treatment.
Clinical studies have demonstrated the effectiveness of one treatment. These studies suggest one injection can last up to 24-36 months.1,2,3*
The injection can be given in a clinic room designated by your clinician. This is usually somewhere in a hospital or medical facility.
Find your closest nSTRIDE® clinic and book a consultation to see if nSTRIDE® is right for you.
2-3 cc of final output will be injected directly in the knee joint.
The nSTRIDE® Procedure
Your local nSTRIDE® clinic takes your blood and we harvest the white blood cells from it. Within 20 minutes blood is processed to make anti-inflammatory proteins. Your local nSTRIDE® clinic injects those proteins back into your joint. Your pain is reduced, your mobility and your disease progression might slow down.
Yes. Your family can attend with you. Your clinician may ask for a limited number or that family members stay outside the room while taking blood samples or during treatment for certain reasons, such as infection policies at the clinical site, but this can be discussed with your clinician.
Kon E. et al. (2018): Two-year clinical outcomes of an Autologous Protein Solution injection for knee osteoarthritis. ICRS 14th World Congress.
A Multicenter, Double-Blind, Randomized, Placebo [Saline]-Controlled Pilot Study of a Single, Intra-Articular Injection of Autologous Protein Solution in Patients with Osteoarthritis of the Knee. Clinical Investigation Report – 36 Month, APSS-33-00, Version 1.0. 14. January 2019.† † As measured by WOMAC pain scores reported by patients continuing follow-up through 3 years (n = 19). 19 out of the original cohort of 31.
van der Weegen W, van Drumpt R, Toler KO, Macenski MM. (2015): Safety and outcomes following a single Autologous Protein Solution injection for knee osteoarthritis: A Pilot Study. International Cartilage Repair Society, #6471, 8-11 May, Chicago, IL.
Matuska A, O’Shaughnessey K, King, W., Woodell-May J. (2013): Autologous solution protects bovine cartilage explants from IL-1. and TNF.-induced cartilage degradation. Journal of Orthopaedic Research. 31(12):1929-35.
O’Shaughnessey K, Matuska A, Hoeppner J, et al. (2014): Autologous protein solution prepared from the blood of osteoarthritic patients contains an enhanced profile of anti-inflammatory cytokines and anabolic growth factors. Journal of Orthopaedic Research. 32(10):1349-1355.
MedlinePlus Medical Encyclopaedia. U.S National Library of Medicine. U.S. National Library of Medicine. n.d. Web. 11 Aug. 2014. http://www.nlm.nih.gov/medlineplus/ency/article/003187.htm.
Nordqvist C. (2014): What Is Arthritis? What Causes Arthritis? Medical News Today. MediLexicon International. n.d. Web. 7 Aug. 2014. http://www.medicalnewstoday.com/articles/7621.php
Osteoarthritis in General Practice: Data and Perspectives. Arthritis Research UK. 19 July 2013. n.d. Web. 8 Aug. 2015. http://www.arthritisresearchuk.org/ policy-and-public-affairs/reports- and-resources/reports.aspx
Arthritis of the Knee-OrthoInfo – AAOS. American Academy of Orthopaedic Surgeons. n.d. Web. 8 Aug. 2014. http://orthoinfo.aaos.org/topic.cfm?topic=A00212
Research Joint Replacement / Knee Pain Knee Pain Overview. Knee Pain Overview: Knee Surgery, Partial/Total Knee Joint Replacements. Biomet, n.d. Web. 11 Aug. 2014. http://www.biomet.com/patients/knee_overview.cfm
Goldring MB. (2000): The role of the chondrocyte in osteoarthritis. Arthritis Rheum. 43(9):1916-1926.
Krueger, P. (2009): Stages of Osteoarthritis: EHow. Demand Media. n.d. Web. 4 Dec. 2014.
Stages of Osteoarthritis: What Everyone Should Know About the Three Stages. Health Guide Info. 24 March 2011. n.d. Web. 4 Dec. 2014.
Bertone AL, Ishihara A, Zekas LJ, et al. (2014): Evaluation of a single intra-articular injection of Autologous Protein Solution for treatment of osteoarthritis in horses. American Journal of Veterinary Medicine. 75(2):141-151.
Woodell-May J, Matuska A, Oyster M, et al. (2011): Autologous protein solution inhibits MMP-13 production by IL-1beta and TNF alpha-stimulated human articular chondrocytes. Journal of Orthopaedic Research. 29 (9):1320-6.
King W, van der Weegen W, Van Drumpt R, Soons H, Toler K, Woodell-May J. (2016): White blood cell concentration correlates with increased concentration of IL-1ra and improvement in WOMAC pain scores in an open-label safety study of autologous protein solution. Journal of Experimental Orthopaedics. 3:9.
Public Health Agency of Canada. Osteoarthritis in Canada. https://www.canada.ca/content/dam/phac- aspc/documents/services/publications/diseases- conditions/osteoarthritis/osteoarthritis-factsheet.pdf
Statistics Canada. Prevalence of osteoarthritis, by age group and site of joint pain, household population aged 20 or older diagnosed with arthritis, Canada excluding territories, 2009. https://www150.statcan.gc.ca/n1/pub/82-003- x/2014009/article/14087/tbl/tbl1-eng.htm
Canadian Institute of Health Information. Annual Report 2019. https://www.cihi.ca/sites/default/files/document/cjrr-annual-report-2019- en-web_0.pdf ^ Laboratory studies are not necessarily indicative of clinical outcomes
* As measured by WOMAC pain scores reported by patients continuing follow-up through 3 years (n = 19).
19 out of the original cohort of 31.
